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Patients with Primary Biliary Cholangitis (PBC) exhibit delayed sleep-wake habits,
disturbed night sleep and daytime sleepiness/fatigue. Such combination of symptoms is
reminiscent of delayed sleep-wake phase disorder (DSPD), which benefits from morning
light treatment. The aim of the present pilot study was to test the effect of morning light
treatment in a group of 13 well-characterized patients with PBC [all females; (mean ± SD)
53 ± 10 years]. Six healthy individuals (4 females, 57 ± 14 years) and 7 patients
with cirrhosis (1 female, 57 ± 12 years) served as controls and diseased controls,
respectively. At baseline, all participants underwent an assessment of quality of life,
diurnal preference, sleep quality/timing (subjective plus actigraphy), daytime sleepiness,
and urinary 6-sulphatoxymelatonin (aMT6s) rhythmicity. Then they underwent a 15-day
course of morning bright light treatment, immediately after getting up (light box, 10,000
lux, 45min) whilst monitoring sleep-wake patterns and aMT6s rhythmicity. At baseline,
both patients with PBC and patients with cirrhosis had significantly worse subjective
sleep quality compared to controls. In patients with PBC, light treatment resulted in
an improvement in subjective sleep quality and a reduction in daytime sleepiness. In
addition, both their sleep onset and get-up time were significantly advanced. Finally,
the robustness of aMT6s rhythmicity (i.e., strength of the cosinor fit) increased after
light administration but post-hoc comparisons were not significant in any of the groups.
In conclusion, a brief course of morning bright light treatment had positive effects on
subjective sleep quality, daytime sleepiness, and sleep timing in patients with PBC. This
unobtrusive, side-effect free, non-pharmacological treatment is worthy of further study.
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INTRODUCTION
Primary biliary cholangitis (PBC) is a rare, immune-mediated cholestatic liver disease (Selmi et al.,
2011; Hirschfield and Gershwin, 2013; Beuers et al., 2015; Webb and Hirschfield, 2017), mostly
affecting women, with the following features: cholestasis, serologic reactivity to antimitochondrial
antibodies (AMA) or specific antinuclear antibody (ANA) reactivity, and histological evidence of
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chronic non-suppurative, granulomatous, lymphocytic small bile
duct cholangitis. The disease is chronic and progressive, and can
result in end-stage liver disease (Carbone et al., 2013; Lammers
et al., 2014; Trivedi et al., 2016). From a clinical stand-point,
the main features of the disease are the persistence of cholestatic
abnormalities and symptoms including pruritus and fatigue. An
association with extra-hepatic autoimmune conditions such as
Sjögren syndrome and autoimmune thyroiditis is also frequent
(Selmi et al., 2011; Hirschfield and Gershwin, 2013; Beuers et al.,
2015).
Patients with PBC exhibit a delay in sleep-wake timing, which
is associated with impaired sleep quality and quality of life
(Montagnese et al., 2013). In addition, an interplay between their
sleep-wake timing and the daytime course of symptoms such as
pruritus and sleepiness has been documented (Montagnese et al.,
2013). Thus a complex set of interacting and possibly conflicting
factors simultaneously impinge on these patients’ sleep and wake
quality, and daytime symptoms such as sleepiness and fatigue
(McDonald et al., 2010).
The combination of delayed sleep habits and impaired sleep
quality is reminiscent of delayed sleep-wake phase disorder
(DSPD), a circadian sleep-wake disorder characterized by
considerable delays in sleep onset/wake-up times compared with
the healthy population (Weitzman et al., 1981; Thorpy et al.,
1988). The goal of DSPD treatment is to resynchronize the
circadian clock timing system with the 24-h light-dark cycle:
structured sleep-wake schedules and avoidance of exposure to
bright light in the evening are advised. In addition, exposure to
bright light shortly after waking up in the morning has been
shown to advance sleep andmelatonin timing (Weyerbrock et al.,
1996; Revell et al., 2005).
The aim of the present study was to test the effect of a 15-
day course of morning bright light treatment on sleep-wake and
circadian variables in a group of well-characterized patients with
non-cirrhotic PBC compared to healthy subjects and a group of
patients with cirrhosis of etiology other than PBC.
PATIENTS AND METHODS
Thirteen consecutive outpatients with PBC [all females; (mean±
SD) 53± 10 years] were enrolled. The diagnosis of PBC had been
established based on the presence of at least two of the following
criteria: AMA antibody or ANA specific antibody (gp210, sp100)
positivity, abnormal alkaline phosphatase levels (at least 1.5 times
the normal value), and/or a compatible liver histology (European
Association for the Study of the Liver, 2017). None of the patients
had advanced (histological stage IV) liver disease; median liver
stiffness at the time of inclusion was 4.7 KPa (range: 3.8–8.1).
All patients were on treatment with ursodeoxycholic acid on
stable dose since PBC diagnosis (13–15 mg/kg/day; time since
diagnosis: 6.7± 6.9 years).
Seven consecutive outpatients with cirrhosis (1 female, 57 ±
12 years) served as diseased controls. The etiology of cirrhosis
was alcohol in 4 patients (including the only female) and viral in
3. Functionally, 4 were classified as Child’s grade A, 2 as B, and 1
as C (Pugh et al., 1973).
Both patients with PBC and patients with cirrhosis were
excluded if they could not comply with the study procedures,
had misused alcohol in the preceding 6 months, had a
history of head injury, cardiovascular/cerebrovascular disease
or significant neurological/psychiatric co-morbidity (including
pharmacologically uncontrolled dysthyroidism).
Six healthy volunteers (4 females; 57 ± 14 years) served as
controls. None had a history, clinical or laboratory evidence of
alcohol misuse, chronic liver disease or neurological/psychiatric
disturbances, drank alcohol in excess of 20 g/day or took
prescription medication.
None of the participants in any of the study groups was on
chronic treatment with drugs known to affect sleep, daytime
vigilance or melatonin production, had traveled across more than
two time zones in the preceding 3 months or undertaken shift
work in the preceding 5 years.
Health-Related Quality of Life
The 36-item short form health profile (SF-36) questionnaire was
used to assess health-related quality of life. This generic, self-
rated, health-related quality of life questionnaire provides an
eight-scale profile, as well as two summary measures (SF-36
summary physical and SF-36 summary mental). The response
to each question is scored, the eight profiles added and the data
transformed into a scale of 0 (worst) to 100 (best) (Ware, 1992).
The questionnaire does not include questions on sleep behavior.
Sleep-Wake Assessment Tools
The Horne-Östberg (HÖ) questionnaire was used to define
diurnal preference as definitely morning (score 70–86),
moderately morning (59–69), intermediate (42–58), moderately
evening (31–41), and definitely evening (16–30) (Horne and
Östberg, 1976).
The Pittsburgh Sleep Quality Index (PSQI) was used to assess
night sleep quality over the preceding month. Questionnaire
responses generate seven components each of which has a
range of 0–3 points (subjective sleep quality, sleep latency,
sleep duration, sleep efficiency, sleep disturbances, use of sleep
medication, and daytime dysfunction), which are summated to
provide the PSQI global score (range: 0–21); scores of>5 identify
“poor” sleepers (Buysse et al., 1989; Curcio et al., 2013).
Sleep diaries were completed daily that included a record of
bed time, sleep onset, time to fall asleep, wake-up time, get-up
time, number/duration of any night awakenings, and daytime
naps. Relevant metrics were calculated, including sleep onset
latency, wakefulness after initial sleep onset, total sleep time, total
time spent in bed, sleep efficiency (time asleep out of total time
in bed, as a percentage) (Carney et al., 2012). Participants were
instructed to complete the sleep diary each morning, after each
night sleep. For purposes of baseline vs. light comparisons, sleep
dairy information was averaged over days 1–7 (always starting on
aMonday) and over days 8–21 (always starting on aMonday; vide
infra—experimental protocol). Effects by day as well as by week
(days 1–7 vs. 8–14 vs. 15–21) were evaluated.
Actigraphy was utilized to assess objective rest-activity
rhythms as a proxy for sleep-wake patterns. An actigraph is
a device that monitors and records body movement via an
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accelerometer. It has the size of a wristwatch and can be
worn on the wrist, ankle or hip for several days without
interfering with normal daily activities (Cellini et al., 2013). It is
commonly used in conjunction with sleep diaries. In the current
study we asked our participants to wear a SOMNOwatchTM
actigraph (SOMNOmedics Gmbh, Randersacker, DE) on their
non-dominant wrist throughout the 26 days of the study,
except when showering or bathing. SOMNOwatchTM is an
FDA-approved device to measure sleep parameters, which have
been shown to be reliable based on a validation study against
polysomnography (Dick et al., 2010). The monitors were set
to record for 30-s epochs and the recordings were downloaded
at the end of the recording period. Time trying to sleep and
get up time were obtained from the corresponding sleep diaries
and were entered into the Domino Light Panel software (v
1.4.0, SOMNOmedics Gmbh, which implements the algorithm
proposed by Gorny et al., 1997). The following indices (also
validated against polysomnography by Dick et al., 2010) were
extracted from the software: total sleep time (minutes); sleep
onset latency (time to fall asleep, minutes); sleep efficiency
{100∗[total sleep time/(bed time – get up time)]}, wake after sleep
onset (time spent awake after sleep onset, minutes), number of
awakenings after sleep onset. For purposes of baseline vs. light
comparisons, actigraphy information was averaged over days 1–
7 (always starting on a Monday) and over days 8–21 (always
starting on a Monday; vide infra—experimental protocol). Both
effects by day and by week (days 1–7 vs. 8–14 vs. 15–21) were
evaluated.
Experimental Protocol and Light
Administration
The study was conducted over 25 days; sleep-wake diaries
were completed daily and an actigraph worn continuously. All
participants underwent the experimental protocol over the same
period of the year (from January to March) to avoid confounding
from daylight saving time and/or major changes in natural
environmental light conditions; each study protocol started on a
Monday. The PSQI and the SF-36 questionnaires were completed
on days 1 (pre-light) and 21 (end of light administration). Two
separate, timed 56-h urine collections (over 2 days and 3 nights,
at 4 h intervals during the day and 8 h intervals at night) were
obtained on study days 3–4 (pre-light) and 22–23 (immediately
after light) for the assessment of urinary 6-sulphatoxymelatonin
(aMT6s; vide infra).
Participants were provided with a Light Box (SAD3 10000
lux—E.M.S. srl Bologna, Italy) and instructed to expose
themselves to light daily for 45min, immediately after getting-
up from day 8 to day 22 (15 days in total). They were asked to
place the Light Box at∼60 cm from their head, to one side, and to
direct their gaze at the Light Box every 10–15min. If they moved
away from the box (for example to go to the toilet or get dressed)
they were instructed to make up for the lost time at the end of
the session. During the entire study period, subjects were asked
to maintain regular sleep-wake schedules and avoid significant
changes to their habitual consumption of coffee, tea, chocolate
and alcoholic beverages. They were also asked to avoid exposure
to bright light and use of mobiles/tablets in the evening and at
night, as long as this did not represent a major change compared
to their regular habits. Compliance was checked by phone every
third day by one of the researchers.
Urinary 6-Sulfatoxymelatonin (aMT6s)
Urine samples were kept at −20◦C and aMT6s concentrations
measured by radioimmunoassay (Stockgrand Ltd., UK). Urine
samples were analyzed in duplicate and all samples from the
same participant were included in the same assay. The inter-assay
coefficients of variation were 8.9% at 2.46 ± 0.22 ng/mL, 9.1% at
10.27 ± 0.93 ng/mL, and 8.9% at 20.73 ± 1.86 ng/mL. Urinary
aMT6s rhythms were evaluated using cosinor analysis, which is
based on the least square approximation of the time series using
a cosine function with a period of 24 h (Minors and Waterhouse,
1988). The following parameters were obtained: acrophase time
(time of peak aMT6s concentration, or maximum of the fitted
cosinor function), mesor (mean aMT6s value for all the samples
included in the cosinor analysis), amplitude (difference between
the mesor and the peak aMT6s concentrations), and % rhythm
(or percentage data variability accounted for by the cosine curve:
100% rhythm = all data points fall on the cosine curve, 0%
rhythm= none of the data points fall on the cosine curve), which
was used as a measure of robustness of the aMT6s rhythmicity.
Cosinor-derived indices were calculated only if the cosinor fit was
significant, based on both the likelihood of the data points fitting
a straight line as opposed to a cosine curve, expressed as a p value,
and on the variable % rhythm. Thus cosinor-derived indices were
considered reliable if the cosinor fit was significant at the 95%
level (p < 0.05) and the variable % rhythm equalled or exceeded
50 (Minors and Waterhouse, 1988).
Ethics
The study was approved by the PadovaUniversity Hospital Ethics
Committee (3639/AO/15, modified 09/03/2016; final approval
17/05/2016) and all participants provided written, informed
consent. The study was conducted according to the Declaration
of Helsinki (Hong Kong Amendment) and Good Clinical
Practice (European) guidelines.
Statistical Analysis
The variables distribution was tested for normality using the
Shapiro–Wilks test. Differences between normally distributed
variables were examined by Student’s t-test/one-way ANOVA;
subsequent between group comparisons were performed
using the Tukey HSD test. Differences between non-normally
distributed variables were examined by Mann–Whitney U-
test/Kruskal–Wallis ANOVA; subsequent between-group
comparisons were performed using the median test for multiple
comparisons. Pre-post light treatment differences were analyzed
by repeated measures ANOVA, by group, and the Tukey test was
used for post-hoc comparisons. The level of significance was set
at p < 0.05 for all analyses.
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RESULTS
Baseline Assessment
There were no significant differences in age between the three
groups (healthy volunteers: 57 ± 14, PBC: 53 ± 10, cirrhosis:
57 ± 12 years) while the expected differences in sex were
observed, with all enrolled PBC patients being females and
patients with cirrhosis being more commonly males. There were
no significant differences between the three groups in terms of
quality of life (Table 1). However, absolute quality of life values
were considerably lower in PBC patients (mental component)
and patients with cirrhosis (physical component) compared to
healthy volunteers. Diurnal preference was comparable in the
three groups (Table 1).
Subjective sleep quality (PSQI Global Score) was significantly
worse in patients with PBC (13.0 ± 4.0) and patients with
cirrhosis (11.3± 4.8) compared to healthy volunteers (5.3± 2.1)
(Table 1). Patients with PBC also fared significantly worse than
healthy volunteers on single PSQI Components 1, 2, 3, and 4
(Table 1).
Sleep timing variables were comparable in the three groups
(Table 1). Similarly, no significant differences were observed in
actigraphy-derived indices; however, due to a technical problem
with two of the actigraphs in use, complete data were available
only for 2 healthy volunteers, 11 patients with PBC, and 5 patients
with cirrhosis (Table 2). Finally, baseline aMT6s rhythmicity
(cosinor indices) were also comparable in the three groups
(Table 3); this may relate to statistical power, as on average,
patients with cirrhosis showed a considerable delay (of ∼3 h) in
aMT6s peak compared to the other two groups (Table 3).
Response to Light
Light exposure had a positive effect on a number of subjective
sleep quality and sleep timing indices, which were significant
in patients with PBC (Table 1 and Supplementary Table 1).
TABLE 1 | Quality of life, diurnal preference questionnaire, sleep questionnaire, and sleep diary variables (mean ± SD), by group and in relation to treatment.
Baseline During light administration
Healthy volunteers PBC Cirrhosis Healthy volunteers PBC Cirrhosis
(n = 6) (n = 13) (n = 7) (n = 6) (n = 13) (n = 7)
Quality of life SF-36 Physical Component 53.51 ± 0.71 41.42 ± 9.21 36.83 ± 12.54 53.49 ± 1.41 44.38 ± 8.24 33.01 ± 10.02
SF-36 Mental Component 47.53 ± 14.14 35.16 ± 9.38 46.51 ± 21.78 54.52 ± 0.71 38.31 ± 10.17 47.52 ± 11.11
Diurnal
preference
Horne-Östberg score 62.16 ± 11.23 55.85 ± 14.48 56.86 ± 11.07 NA NA NA
Subjective
sleep quality
(PSQI)
Component 1—Subjective sleep
quality (0-3)
0.8 ± 0.4 2.1 ± 0.9# 1.8 ± 0.9 0.8 ± 0.4 1.1 ± 0.8* 1.1 ± 0.7
Component 2–Sleep latency
(0-3)
1.0 ± 0.9 2.2 ± 0.7# 2.0 ± 1.1 1.2 ± 1.2 1.7 ± 1.0 1.7 ± 1.2
Component 3—Sleep duration
(0-3)
0.7 ± 0.5 2.1 ± 0.8# 1.7 ± 0.9 0.3 ± 0.5 1.5 ± 1.1 1.3 ± 0.9
Component 4—Sleep efficiency
(0-3)
0.3 ± 0.5 1.8 ± 1.0# 1.3 ± 1.2 0.2 ± 0.4 1.7 ± 1.0 0.8 ± 1.1
Component 5—Sleep
disturbance (0–3)
1.2 ± 0.4 1.7 ± 0.6 1.7 ± 0.8 1.2 ± 0.4 1.5 ± 0.8 1.0 ± 0.8
Component 6—Use of sleep
medication (0–3)
0.2 ± 0.4 1.2 ± 1.2 0.7 ± 1.2 0.0 ± 0.0 0.6 ± 1.2 0.6 ± 1.0
Component 7—Daytime
dysfunction (0–3)
1.2 ± 0.7 1.9 ± 0.6 2.0 ± 0.8 0.8 ± 0.4 1.3 ± 0.5* 1.9 ± 0.4
Global score (0–21) 5.3 ± 2.1 13.1 ± 4.0# 11.3 ± 4.8N 4.5 ± 1.5 9.4 ± 3.9* 8.4 ± 4.5
Sleep diaries Bed time (hh:mm) 23 : 58 ± 00 :57 23 : 26 ± 00 : 55 23 : 57 ± 01 :07 23 :29 ± 00 : 49 23 : 03 ± 00 : 50 00 : 01 ± 00 : 57
Time try to sleep (hh:mm) 00 : 15 ± 00 :54 23 : 57 ± 01 : 01 00 : 11 ± 01 :00 23 :45 ± 00 : 40 23 : 34 ± 00 : 52 00 : 12 ± 00 : 53
Sleep onset latency (min) 8.01 ± 4.81 30.82 ± 16.43 37.62 ± 57.26 6.03 ± 4.01 25.39 ± 16.63 37.7 ± 42.04
Sleep onset (hh:mm) 00 : 23 ± 00 :50 00 : 32 ± 01 : 12 00 : 48 ± 01 :49 23 :51 ± 00 : 37 23 : 56 ± 01 : 06* 00 : 51 ± 01 : 35
Night awakenings (n) 1.39 ± 1.15 1.84 ± 0.85 2.83 ± 1.95 1.17 ± 0.87 1.4 ± 0.76 2.44 ± 1.81
Wake up time (hh:mm) 06 : 54 ± 00 :31 06 : 39 ± 01 : 22 07 : 26 ± 00 :47 06 :36 ± 00 : 24 06 : 30 ± 01 : 08 07 : 30 ± 00 : 52
Get up time (hh:mm) 07 : 12 ± 00 :37 07 : 21 ± 01 : 20 07 : 56 ± 00 :56 06 :58 ± 00 : 37 06 : 58 ± 01 : 07* 07 : 51 ± 00 : 53
Daytime naps (n) 0.2 ± 0.4 0.4 ± 0.4 0.8 ± 0.5 0.5 ± 0.4 0.3 ± 0.4 0.7 ± 0.4
Time spent in bed (hours) 7.2 ± 0.9 7.8 ± 1.0 8.0 ± 0.7 7.5 ± 1.1 7.9 ± 1.2 7.8 ± 0.8
Length of sleep (hours) 6.5 ± 0.6 6.1 ± 1.1 6.7 ± 1.4 4.0 ± 1.7 5.5 ± 1.3 5.6 ± 1.3
Sleep efficiency (%) 90.5 ± 0.8 78.3 ± 11.6 82.5 ± 14.0 91.5 ± 5.4 83.1 ± 10.2 84.6 ± 11.0
#PBC vs. healthy volunteers: p < 0.05 NCirrhosis vs. healthy volunteers: p < 0.05.
*PBC light treatment vs. PBC baseline: p < 0.05.
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TABLE 2 | Actigraphic sleep-wake indices (mean ± SD), by group and in relation to treatment.
Actigraphy indices Baseline During light administration
Healthy volunteers PBC Cirrhosis Healthy volunteers PBC Cirrhosis
(n = 2) (n = 11) (n = 5) (n = 2) (n = 11) (n = 5)
Time in bed (min) 399 ± 54 437 ± 51 463 ± 38 404 ± 96 437 ± 34 465 ± 50
Total sleep time (min) 383 ± 50 403 ± 63 406 ± 38 386 ± 90 405 ± 45 428 ± 56
Sleep onset latency (min) 7 ± 0 11 ± 16 13 ± 15 7 ± 0 6 ± 8 8 ± 8
Wake after sleep onset (min) 9 ± 4 23 ± 7 44 ± 46 10 ± 5 26 ± 14 29 ± 26
Number of awakenings (n) 2.6 ± 0.3 2.4 ± 1.3 4.9 ± 2.5 2.2 ± 0.9 2.5 ± 0.7 4.1 ± 2.9
Sleep efficiency (%) 96 ± 1 92 ± 17 88 ± 11 96 ± 1 93 ± 4 92 ± 7
TABLE 3 | 6-sulfatoxymelatonin (aMT6s) cosinor indices (mean ± SD), by group and in relation to treatment.
Cosinor indices Baseline After light administration
Healthy volunteers PBC Cirrhosis Healthy volunteers PBC Cirrhosis
(n = 5) (n = 7) (n = 5) (n = 5) (n = 7) (n = 5)
Mesor (pg/ml) 12.9 ± 7.3 8.7 ± 4.5 7.0 ± 5.4 12.6 ± 5.8 8.4 ± 5.7 9.3 ± 8.9
Amplitude (pg/ml) 17.0 ± 11.2 11.4 ± 7.0 7.5 ± 8.7 14.9 ± 10.0 10.1 ± 7.9 11.0 ± 12.6
Acrophase (clock time, hh:mm) 03 : 33 ± 01 : 24 04 : 00 ± 01 :82 07 : 37 ± 07 : 45 03 : 49 ± 00 : 45 03 : 48 ± 01 : 09 08 : 00 ± 07 : 01
Rhythm (%) 84 ± 7 72 ± 17 68 ± 13 87 ± 6 81 ± 12 81 ± 16
These data refer only to individuals whose aMT6s cosinor fit was significant (p < 0.05 and % rhythm ≥50) both at baseline and after treatment.
FIGURE 1 | Pittsburgh Sleep Quality Index (PSQI) Global Score (A) and Component 7 (Dysfunction due to sleepiness; (B) before (white columns) and after 2 weeks of
light administration (gray columns), by patient category (HV, healthy volunteers; PBC, Primary Biliary Cholangitis). (A) Patient category: p = 0.007; treatment:
p < 0.001; patient category×treatment: p = 0.120; ∧post-hoc significant for PBC: p < 0.001. (B) Patient category: p = 0.010; treatment: p = 0.011; patient
category×treatment: p = 0.280; ∧post-hoc significant for PBC: p = 0.021.
A significant reduction in PSQI Global Score was observed
in patients with PBC following light administration (9.38 ±
3.95) compared to baseline (13.08 ± 4.05, post-hoc p < 0.001;
Table 1, Figure 1A), together with a reduction in the PSQI
Component 7 (dysfunction due to sleepiness) [1.3 ± 0.5 (light)
vs. 1.9 ± 0.6 (baseline), post-hoc p < 0.01; Table 1, Figure 1B).
Furthermore, light treatment also resulted in significantly earlier
sleep onset (23:56 ± 01:06 vs. 00:32 ± 01:12, post-hoc p = 0.047;
Table 1, Figure 2A) and earlier get-up time (06:58 ± 01:07 vs.
07:21 ± 01:20, post-hoc p = 0.026; Table 1, Figure 2B). No
significant differences were observed in actigraphy indices during
light administration in any of the groups (Table 2). However,
absolute values for wake after sleep onset decreased during
light administration in patients with cirrhosis (Table 2), and
the difference between baseline and treatment was significant
(p < 0.05) when comparisons were confined to this patient
group. Analyses by day and by week confirmed the averaged data
analyses.
Finally, 5 healthy volunteers, 7 patients with PBC and 5
patients with cirrhosis had significant cosinor fits for their
aMT6s rhythms both at baseline and after light treatment.
Robustness of aMT6s rhythmicity (i.e., strength of the cosinor
fit expressed as a percentage rhythm) significantly increased
after light administration (Figure 3) but post-hoc comparisons
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were not significant for any of the groups (Table 3 and
Supplementary Table 1). Of note, the post-light treatment
improvement in cosine fits in the PBC and cirrhosis patients
could not be attributed to differences in urine sample number
(i.e., random variability in number of bladder emptying episodes
between the pre- and post-light series) as these were comparable
(n = 25 ± 11 at baseline and n = 22 ± 10 after light; p = 0.41).
Three (one healthy volunteer, one patient with PBC, and one
patient with cirrhosis) representative aMT6s histograms and
pertinent cosinor fits, at baseline and after light treatment, are
presented in Figure 4. In all three participants the cosinor fit was
significant both at baseline and after light administration, the fit
improving considerably after light administration. No significant
changes were observed in the aMT6s cosinor indices mesor,
amplitude and acrophase after light administration.
DISCUSSION
In the present study, we confirmed that non-cirrhotic patients
with PBC and patients with cirrhosis of etiology other than PBC
exhibit impaired sleep quality compared to healthy volunteers.
In addition, we observed that a brief 15-day course of morning
bright light treatment significantly improved both sleep quality
and sleep timing in patients with PBC. Specifically, light exposure
resulted in improved subjective night sleep quality, reduced
daytime sleepiness and earlier sleep onset and get-up times.
In addition, more robust aMT6s rhythmicity was observed in
PBC and cirrhotic patients after light treatment. These are novel
and potentially relevant observations that need to be confirmed
and studied further for their potential efficacy in terms of
amelioration of specific disease symptoms.
In patients with PBC, excessive daytime somnolence has been
linked to fatigue but a clear association between fatigue and
overall sleep quality has not yet been documented (Newton et al.,
2006; Montagnese et al., 2013). In the present study, we observed
amelioration of overall sleep quality, advanced sleep onset and
get-up times, and a reduction in daytime sleepiness in response to
bright light treatment. While fatigue was not formally assessed, it
is possible to speculate that the symptoms “daytime dysfunction
due to somnolence” and “fatigue” may overlap, at least to some
extent, and thus hypothesize that morning bright light treatment
may have some beneficial effect on fatigue, one of the most
invalidating symptoms of PBC.
Using the SF-36 questionnaire, no significant differences in
quality of life were observed between patients with PBC, patients
with cirrhosis and healthy controls. No significant changes in
quality of life were observed after light treatment either. This
may be related to the limited sample size and insufficient
statistical power. In addition, the SF-36 is a generic quality of
life questionnaire which does not explore the quality of sleep
and quality of wake domains. More specific tools, for example
the PBC-40, which specifically covers the impact of fatigue and
pruritus (Jacoby et al., 2005), could be utilized in future.
FIGURE 3 | Robustness of the 6-sulphatoxymelatonin (aMT6s) rhythm (i.e.,
percentage data variability accounted for by the cosine curve, % rhythm)
before (white columns) and after light administration (gray columns), by patient
category (HV, healthy volunteers; PBC, Primary Biliary Cholangitis). Patient
category: p = 0.250; treatment: p = 0.035; patient category×treatment:
p = 0.601.
FIGURE 2 | Sleep diary-based sleep onset (clock time; A) and get up time (clock time; B) before (white columns) and during light administration (gray columns), by
patient category (HV, healthy volunteers; PBC, Primary Biliary Cholangitis). (A) Patient category: p = 0.500; treatment: p = 0.019; patient category×treatment:
p = 0.140; ∧post-hoc significant for PBC: p = 0.047. (B) Patient category: p = 0.270; treatment: p = 0.010; patient category×treatment: p = 0.330; ∧post-hoc
significant for PBC: p = 0.026.
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FIGURE 4 | Sequential 56-h (three nights and 2 days) aMT6s excretion (ng/h, gray histograms, left y axis; width of the histogram = time between first and last bladder
emptying over the collection period) in a healthy volunteer [female, 73 years of age; prior to (A) and after light administration (B)], a patient with primary biliary
cholangitis [female, 65 years of age; prior to (C) and after light administration (D)], and a patient with cirrhosis [female, 50 years of age; prior to (E) and after light
administration (F)]. Urinary aMT6s concentrations are high during night sleep and low during the waking day. Continuous line: fitted cosinor function, which shows the
profile of urinary aMT6s concentrations over the 24-h period and allows calculation of a set of cosinor-derived aMT6s parameters (right y axis: amplitude of the cosinor
fit in ng/h of aMT6s). In all three participants the cosinor fit was significant both at baseline and after light administration, the fit improving considerably after light
administration. Healthy volunteer: % rhythm: 77; p = 0.003 at baseline (A) and % rhythm: 91; p < 0.0001 after light administration (B); patient with primary biliary
cholangitis: % rhythm: 59; p = 0.028 at baseline (C) and % rhythm: 95; p < 0.0001 after light administration (D); patient with cirrhosis: % rhythm: 60; p = 0.026 at
baseline (E) and % rhythm: 88; p < 0.001 after light administration (F).
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In the present study, patients with cirrhosis showed a very
delayed aMT6s acrophase time compared to PBC and healthy
volunteers, although the differences were not significant, most
likely due to small sample size and considerable inter-individual
variability, which has been documented before (Montagnese
et al., 2015). Delayed sleep-wake (Córdoba et al., 1998),
melatonin (Steindl et al., 1995, 1997; Velissaris et al., 2009;
Montagnese et al., 2010), urinary aMT6s (Montagnese et al.,
2009), and cortisol rhythms (Montagnese et al., 2011) have all
been previously observed in these patients. Delayed melatonin,
aMT6s and cortisol rhythms in this patient population are
believed to be mixed in origin, i.e., due to the additive effects
of impaired light sensitivity of the retinal-hypothalamic-pineal
pathway (Montagnese et al., 2010), and reduced overnight
melatonin clearance, especially in patients with decompensated
liver disease and severe hepatic failure (Steindl et al., 1997;
Montagnese et al., 2010). It is therefore interesting that the small
group of patients with cirrhosis recruited in the present study,
who were better compensated than those we have previously
studied, also reflects the above features, with delayed aMT6s
rhythms. In the present study morning bright light also had
limited effects in patients with cirrhosis, which confirms a
previous study of hospitalized decompensated patients with
cirrhosis by our own group (De Rui et al., 2011). As this study
(De Rui et al., 2011) was performed in inpatients with cirrhosis
with severe hepatic failure, at the time we suspected that the
limited response to light might have been due to the severity
of the underlying disease, and possibly also to the added sleep-
wake difficulties associated with hospitalization. By contrast, the
present study appears to indicate that the response is also limited
in better compensated outpatients, suggesting that alternative,
cirrhosis-related mechanisms may be involved and that impaired
sensitivity to light cannot be corrected simply by administering
stronger/different spectrum light. The reasons why in the present
study subjective sleep quality seemed to improve slightly despite
the lack of an obvious aMT6s response are numerous. For
example, it is possible that the observed increase in aMT6s
rhythmicity, despite the lack of significant changes in aMT6s
timing, may result in an improvement in sleep quality.
Our study has a number of limitations, which include: (i)
its relatively small size and different sex ratio among the three
study groups, largely due to the fact that PBC is a predominantly
female disease whilst cirrhosis is predominantly male disease;
(ii) the use of a generic quality of life questionnaire instead
of specific assessment of fatigue in patients with PBC; (iii) the
use of the PSQI sleep quality questionnaire, which covers sleep
the month prior, thus has some degree of overlap between our
baseline and post-treatment assessments; and (iv) the lack of
a placebo arm, which always represents a significant problem
in light treatment trials. To date, only installed placebo light
facilities have been tested (Riemersma-van der Lek et al., 2008),
for which a treatment effect cannot be excluded andwhich are not
applicable in the outpatient setting. Placebo light boxes (e.g., with
lower light intensity and modified spectrum) could obviously be
designed but the producers’ interest would be limited, and some
treatment effect could not be excluded. Despite these limitations,
we were able to detect a significant response to light treatment in
patients with PBC, whose subjective sleep quality, sleep timing
and urinary melatonin rhythmicity all improved, at least to
some extent, after the course of morning bright light treatment.
These results are clinically relevant and represent justification
for a larger multicentre trial, with outcomes to include sleep-
wake profiles, circadian hormones, fatigue, and quality of life.
Future studies may also benefit from the fact that outpatient
light administration tools other than light boxes have become
available, e.g., light glasses (Langevin et al., 2014), which do
not require the patient to stay seated in front of the light box
and may improve compliance in individuals who have morning
commitments.
In conclusion, should our results be confirmed in larger,
possibly multicentre studies, morning bright light would
represent a promising, unobtrusive and side-effect free treatment
for patients with PBC with sleep-wake disturbances and daytime
dysfunction.
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